Management of venous thromboembolism in patients with primary and metastatic brain tumors

Journal of Clinical Oncology

Volumn 24, Issue 8, 2006, Pages 1310-1318

  Gerber, David E ^a   Grossman, Stuart A ^a   Streiff, Michael B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; CIMETIDINE; COTRIMOXAZOLE; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; FRESH FROZEN PLASMA; HEPARIN; LEPIRUDIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENYTOIN; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TINZAPARIN; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT;

BLEEDING; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRAIN TUMOR; DRUG ANTAGONISM; DRUG HALF LIFE; HUMAN; INCIDENCE; NEUROSURGERY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM; RISK; THROMBOEMBOLISM;

ANTICOAGULANTS; BRAIN NEOPLASMS; HUMANS; RISK; THROMBOEMBOLISM; VENA CAVA FILTERS;

EID: 33644871901     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.6656     Document Type: Review

References (110)

1. Trousseau A: Phlegmasia alba dolens. Lectures on Clinical Medicine 5:281-331, 1868
2. Heit JA, Silverstein MD, Mohr DN, et al: Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med 160:809-815, 2000
3. Blom JW, Doggen CJ, Osanto S, et al: Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715-722, 2005
4. Hillen HF: Thrombosis in cancer patients. Ann Oncol 11:273-276, 2000 (suppl 3)
5. Alpert JS, Dalen JE: Epidemiology and natural history of venous thromboembolism. Prog Cardiovasc Dis 36:417-422, 1994
6. Horlander KT, Mannino DM, Leeper KV: Pulmonary embolism mortality in the united states, 1979-1998: An analysis using multiple-cause mortality data. Arch Intern Med 163:1711-1717, 2003
7. Goldhaber SZ, Visani L, De Rosa M: Acute pulmonary embolism: Clinical outcomes in the international cooperative pulmonary embolism registry (ICOPER). Lancet 353:1386-1389, 1999
8. Constantini S, Kornowski R, Pomeranz S, et al: Thromboembolic phenomena in neurosurgical patients operated upon for primary and metastatic brain tumors. Acta Neurochir (Wien) 109:93-97, 1991
9. Hylek EM, Singer DE: Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 120:897-902, 1994
10. Sjoblom L, Hardemark HG, Lindgren A, et al: Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: A Swedish multicenter study. Stroke 32:2567-2574, 2001
11. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
12. Levitan N, Dowlati A, Remick SC, et al: Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy, risk analysis using medicare claims data. Medicine (Baltimore) 78: 285-291, 1999
13. Sorensen HT, Mellemkjaer L, Steffensen FH, et al: The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338:1169-1173, 1998
14. Ruff RL, Posner JB: Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 13:334-336, 1983
15. Dhami MS, Bona RD, Calogero JA, et al: Venous thromboembolism and high grade gliomas. Thromb Haemost 70:393-396, 1993
16. Cheruku R, Tapazoglou E, Ensley J, et al: The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer 68:2621-2624, 1991
17. Quevedo JF, Buckner JC, Schmidt JL, et al: Thromboembolism in patients with high-grade glioma. Mayo Clin Proc 69:329-332, 1994
18. Valladares JB, Hankinson J: Incidence of lower extremity deep vein thrombosis in neurosurgical patients. Neurosurgery 6:138-141, 1980
19. Sawaya R, Zuccarello M, Elkalliny M, et al: Postoperative venous thromboembolism and brain tumors: Part I - Clinical profile. J Neurooncol 14:119-125, 1992
20. Sawaya R, Decourteen-Meyers G, Copeland B: Massive preoperative pulmonary embolism and suprasellar brain tumor: Case report and review of the literature. Neurosurgery 15:566-571, 1984
21. Thoron L, DeAngelis LM: Thromboembolism in primary central nervous system lymphoma (PCNSL). Proc Am Soc Clin Oncol 10:128, 1991 (abstr 381)
22. Rodas RA, Fenstermaker RA, McKeever PE, et al: Correlation of intraluminal thrombosis in brain tumor vessels with postoperative thrombotic complications: A preliminary report. J Neurosurg 89:200-205, 1998
23. Goldschmidt N, Linetsky E, Shalom E, et al: High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer 98:1239-1242, 2003
24. Ottinger H, Belka C, Kozole G, et al: Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: Incidence, causes and prognostic relevance. Eur J Haematol 54:186-194, 1995
25. Seifter EJ, Young RC, Longo DL: Deep venous thrombosis during therapy for Hodgkin's disease. Cancer Treat Rep 69:1011-1013, 1985
26. Chan AT, Atiemo A, Diran LK, et al: Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. J Thromb Thrombolysis 8:139-142, 1999
27. Marras LC, Geerts WH, Perry JR: The risk of venous thromboembolism is increased throughout the course of malignant glioma: An evidence-based review. Cancer 89:640-646, 2000
28. Kayser-Gatchalian MC, Kayser K: Thrombosis and intracranial tumors. J Neurol 209:217-224, 1975
29. Brandes AA, Scelzi E, Salmistraro G, et al: Incidence of risk of thromboembolism during treatment high-grade gliomas: A prospective study. Eur J Cancer 33:1592-1596, 1997
30. Thoron L, Arbit E: Hemostatic changes in patients with brain tumors. J Neurooncol 22:87-100, 1994
31. Iberti TJ, Miller M, Abalos A, et al: Abnormal coagulation profile in brain tumor patients during surgery. Neurosurgery 34:389-395, 1994
32. Sciacca FL, Ciusani E, Silvani A, et al: Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res 10:1312-1317, 2004
33. Heesen M, Kemkes-Matthes B, Deinsberger W, et al: Coagulation alterations in patients undergoing elective craniotomy. Surg Neurol 47:35-38, 1997
34. Sonaglia F, Agnelli G, Baroni M, et al: Preoperative plasma levels of soluble fibrin polymers correlate with the development of deep vein thrombosis after elective neurosurgery. Blood Coagul Fibrinolysis 10:459-463, 1999
35. Sawaya R, Glas-Greenwalt P: Postoperative venous thromboembolism and brain tumors: Part II - Hemostatic profile. J Neurooncol 14:127-134, 1992
36. Sawaya RE, Ligon BL: Thromboembolic complications associated with brain tumors. J Neurooncol 22:173-181, 1994
37. Streiff MB, Segal J, Grossman SA, et al: ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer 100:1717-1723, 2004
38. Hamada K, Kuratsu J, Saitoh Y, et al: Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 77:1877-1883, 1996
39. Walsh DC, Kakkar AK: Thromboembolism in brain tumors. Curr Opin PuLm Med 7:326-331, 2001
40. Brotman DJ, Girod JP, Posch A, et al: Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res, July 7, 2005 [epub ahead of print]
41. Levin JM, Schiff D, Loeffler JS, et al: Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 43:1111-1114, 1993
42. Pruitt AA: Treatment of medical complications in patients with brain tumors. Curr Treat Options Neurol 7:323-336, 2005
43. So W, Hugenholtz H, Richard MT: Complications of anticoagulant therapy in patients with known central nervous system lesions. Can J Surg 26:181-183, 1983
44. Muchmore JH, Dunlap JN, Culicchia F, et al: Deep vein thrombophlebitis and pulmonary embolism in patients with malignant gliomas. South Med J 82:1352-1356, 1989
45. Schiff D, DeAngelis LM: Therapy of venous thromboembolism in patients with brain metastases. Cancer 73:493-498, 1994
46. Streiff MB: Vena cavai filters: A comprehensive review. Blood 95:3669-3677, 2000
47. Olin JW, Young JR, Graor RA, et al: Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors, anticoagulants or inferior vena cava filter? Arch Intern Med 147:2177-2179, 1987
48. Knovich MA, Lesser GJ: The management of thromboembolic disease in patients with central nervous system malignancies. Curr Treat Options Oncol 5:511-517, 2004
49. Norris LK, Grossman SA: Treatment of thromboembolic complications in patients with brain tumors. J Neurooncol 22:127-137, 1994
50. Wen PY, Marks PW: Medical management of patients with brain tumors. Curr Opin Oncol 14:299-307, 2002
51. Choucair AK, Silver P, Levin VA: Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg 66:357-358, 1987
52. Levine MN, Raskob G, Beyth RJ, et al: Hemorrhagic complications of anticoagulant treatment: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:2873-310S, 2004 (suppl 3)
53. Hirsh J, Warkentin TE, Shaughnessy SG, et al: Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119:64S-94S, 2001 (suppl 1)
54. Koopman MM, Prandoni P, Piovella F, et al: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home, the tasman study group. N Engl J Med 334:682-687, 1996
55. Levine M, Gent M, Hirsh J, et al: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334:677-681, 1996
56. Buller HR, Agnelli G, Hull RD, et al: Antithrombotic therapy for venous thromboembolic disease: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126: 401S-428S, 2004 (suppl 3)
57. Hutten BA, Prins MH, Gent M, et al: Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis. J Clin Oncol 18:3078-3083, 2000
58. Palareti G, Legnani C, Lee A, et al: A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 84:805-810, 2000
59. Prandoni P, Lensing AW, Piccioli A, et al: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484-3488, 2002
60. Lee AY, Levine MN, Baker RI, et al: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146-153, 2003
61. Altschuler E, Moosa H, Selker RG, et al: The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors. Neurosurgery 27:74-77, 1990
62. Holbrook AM, Pereira JA, Labiris R, et al: Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165:1095-1106, 2005
63. Ansell J, Hirsh J, Poller L, et al: The pharmacology and management of the vitamin K antagonists: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:204S-233S, 2004 (suppl 3)
64. Dennis MS, Bamford JM, Molyneux AJ, et al: Rapid resolution of signs of primary intracerebral haemorrhage in computed tomograms of the brain. BMJ (Clin Res Ed) 295:379-381, 1987
65. Wardlaw JM, Keir SL, Seymour J, et al: What is the best imaging strategy for acute stroke? Health Technol Assess 8:iii, ix-x, 1-180, 2004
66. Weisberg LA: Hemorrhagic metastatic intracranial neoplasms: Clinical-computed tomographic correlations. Comput Radiol 9:105-114, 1985
67. Kondziolka D, Bernstein M, Resch L, et al: Significance of hemorrhage into brain tumors: Clinicopathological study. J Neurosurg 67:852-857, 1987
68. Wakai S, Yamakawa K, Manaka S, et al: Spontaneous intracranial hemorrhage caused by brain tumor: Its incidence and clinical significance. Neurosurgery 10:437-444, 1982
69. Morales A, Adelstein DJ: Should a patient with a brain tumor receive anticoagulation for a thromboembolic event? Cleve Clin J Med 68:13, 16, 2001
70. Heres EK, Speight K, Benckart D, et al: The clinical onset of heparin is rapid. Anesth Analg 92:1391-1395, 2001
71. Wolfe MW: Intracranial hemorrhage during systemic anticoagulation in patients with cerebral metastasis. Arch Intern Med 148:1878-1879, 1988
72. Bates SM, Ginsberg JS: Clinical practice: Treatment of deep-vein thrombosis. N Engl J Med 351:268-277, 2004
73. Lazio BE, Simard JM: Anticoagulation in neurosurgical patients. Neurosurgery 45:838-848, 1999
74. Schaible KL, Smith LJ, Fessier RG, et al: Evaluation of the risks of anticoagulation therapy following experimental craniotomy in the rat. J Neurosurg 63:959-962, 1985
75. Laohaprasit V, Mayberg MR: Risks of anticoagulation therapy after experimental corticectomy in the rat. Neurosurgery 32:625-629, 1993
76. Bertram M, Bonsanto M, Hacke W, et al: Managing the therapeutic dilemma: Patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation. J Neurol 247:209-214, 2000
77. Wijdicks EF, Scott JP: Pulmonary embolism associated with acute stroke. Mayo Clin Proc 72: 297-300, 1997
78. Kelly J, Hunt BJ, Lewis RR, et al: Anticoagulation or inferior vena cava filter placement for patients with primary intracerebral hemorrhage developing venous thromboembolism? Stroke 34: 2999-3005, 2003
79. Barton AL, Dudley NJ: Caval filter placement for pulmonary embolism in a patient with a deep vein thrombosis and primary intracerebral haemorrhage. Age Ageing 31:144-146, 2002
80. Wani M, Nga E, Navaratnasingham R: Should a patient with primary intracerebral haemorrhage receive antiplatelet or anticoagulant therapy? BMJ 331:439-442, 2005
81. Antman EM, Anbe DT, Armstrong PW, et al: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: A report of the american college of Cardiology/American heart association task force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 44:671-719, 2004
82. Carman TL, Kanner AA, Barnett GH, et al: Prevention of thromboembolism after neurosurgery for brain and spinal tumors. South Med J 96:17-22, 2003
83. Stephens PH, Healy MT, Smith M, et al: Prophylaxis against thromboembolism in neurosurgical patients: A survey of current practice in the united kingdom. Br J Neurosurg 9:159-163, 1995
84. Bostrom S, Holmgren E, Jonsson O, et al: Post-operative thromboembolism in neurosurgery. A study on the prophylactic effect of calf muscle stimulation plus dextran compared to low-dose heparin. Acta Neurochir (Wien) 80:83-89, 1986
85. Turpie AG, Hirsh J, Gent M, et al: Prevention of deep vein thrombosis in potential neurosurgical patients. A randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. Arch Intern Med 149:679-681, 1989
86. Bucci MN, Papadopoulos SM, Chen JC, et al: Mechanical prophylaxis of venous thrombosis in patients undergoing craniotomy: A randomized trial. Surg Neurol 32:285-288, 1989
87. Skillman JJ, Collins RE, Coe NP, et al: Prevention of deep vein thrombosis in neurosurgical patients: A controlled, randomized trial of external pneumatic compression boots. Surgery 83:354-358, 1978
88. Comerota AJ, Katz ML, White JV: Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail? Am J Surg 164:265-268, 1992
89. Cornwell EE 3rd, Chang D, Velmahos G, et al: Compliance with sequential compression device prophylaxis in at-risk trauma patients: A prospective analysis. Am Surg 68:470-473, 2002
90. Frim DM, Barker FG 2nd, Potetti CE, et al: Postoperative low-dose heparin decreases thromboembolic complications in neurosurgical patients. Neurosurgery 30:830-833, 1992
91. Macdonald RL, Amidei C, Lin G, et al: Safety of perioperative subcutaneous heparin for prophylaxis of venous thromboembolism in patients undergoing craniotomy. Neurosurgery 45:245-252, 1999
92. Cerrato D, Ariano C, Fiacchino F: Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients. J Neurosurg 49:378-381, 1978
93. Barnett HG, Clifford JR, Llewellyn RC: Safety of mini-dose heparin administration for neurosurgical patients. J Neurosurg 47:27-30, 1977
94. Nurmohamed MT, van Riel AM, Henkens CM, et al: Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 75:233-238, 1996
95. Iorio A, Agnelli G: Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: A meta-analysis. Arch Intern Med 160:2327-2332, 2000
96. Goldhaber SZ, Dunn K, Gerhard-Herman M, et al: Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 122:1933-1937, 2002
97. Dickinson LD, Miller LD, Patel CP, et al: Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 43:1074-1081, 1998
98. Bergqvist D, Lindblad B, Matzsch T: Risk of combining low molecular weight heparin for thromboprophylaxis and epidural or spinal anesthesia. Semin Thromb Hemost 1:147-151, 1993 (suppl 19)
99. Kleindienst A, Harvey HB, Mater E, et al: Early antithrombotic prophylaxis with low molecular weight heparin in neurosurgery. Acta Neurochir (Wien) 145:1085-1091, 2003
100. Gerlach R, Scheuer T, Beck J, et al: Risk of postoperative hemorrhage after intracranial surgery after early nadroparin administration: Results of a prospective study. Neurosurgery 53:1028-1035, 2003
101. Manno EM, Atkinson JL, Fulgham JR, et al: Emerging medical and surgical management strategies in the evaluation and treatment of intracerebral hemorrhage. Mayo Clin Proc 80:420-433, 2005
102. Broderick JP, Adams HP Jr, Barsan W, et al: Guidelines for the management of spontaneous intracerebral hemorrhage: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 30:905-915, 1999
103. Warkentin TE, Crowther MA: Reversing anticoagulants both old and new. Can J Anaesth 49:S11-S25, 2002 (suppl)
104. Crowther MA, Berry LR, Monagle PT, et al: Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. BrJ Haematol 116:178-186, 2002
105. Baker RI, Coughlin PB, Gallus AS, et al: Warfarin reversal: Consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 181:492-497, 2004
106. Mayer SA: Ultra-early hemostatic therapy for intracerebral hemorrhage. Stroke 34:224-229, 2003
107. Sorensen B, Johansen P, Nielsen GL, et al: Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: Clinical and biochemical aspects. Blood Coagul Fibrinolysis 14:469-477, 2003
108. Bijsterveld NR, Moons AH, Boekholdt SM, et al: Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106:2550-2554, 2002
109. Ng HJ, Koh LP, Lee LH: Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann Hematol 82:257-258, 2003
110. Stratmann G, deSilva AM, Tseng EE, et al: Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg 98:1635-1639, 2004